Boston Scientific Corp. (BSX)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Boston Scientific Corp. (BSX)
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Key Insights
Critical company metrics and information
Share Price
$89.36Market Cap
$131.69 BillionTotal Outstanding Shares
1.47 Billion SharesTotal Employees
48,000Dividend
No dividendIPO Date
May 18, 1992SIC Description
Surgical & Medical Instruments & ApparatusHomepage
https://www.bostonscientific.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Investing Activities, Continuing | $-3.04 Billion |
Exchange Gains/Losses | $2.00 Million |
Net Cash Flow From Investing Activities | $-3.04 Billion |
Net Cash Flow From Financing Activities | $1.61 Billion |
Net Cash Flow | $1.52 Billion |
Net Cash Flow From Operating Activities | $2.94 Billion |
Net Cash Flow, Continuing | $1.51 Billion |
Net Cash Flow From Operating Activities, Continuing | $2.94 Billion |
Net Cash Flow From Financing Activities, Continuing | $1.61 Billion |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Operating Expenses | $8.46 Billion |
Other Operating Expenses | $2.71 Billion |
Net Income/Loss Available To Common Stockholders, Basic | $1.79 Billion |
Income/Loss From Continuing Operations After Tax | $1.79 Billion |
Diluted Earnings Per Share | $1.21 |
Cost Of Revenue | $4.94 Billion |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Selling, General, and Administrative Expenses | $5.75 Billion |
Revenues | $15.91 Billion |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Income/Loss From Continuing Operations Before Tax | $2.20 Billion |
Net Income/Loss Attributable To Parent | $1.79 Billion |
Nonoperating Income/Loss | $-310.00 Million |
Basic Average Shares | $2.95 Billion |
Income Tax Expense/Benefit | $414.00 Million |
Basic Earnings Per Share | $1.22 |
Benefits Costs and Expenses | $13.71 Billion |
Net Income/Loss Attributable To Noncontrolling Interest | $-18.00 Million |
Diluted Average Shares | $2.97 Billion |
Operating Income/Loss | $2.51 Billion |
Interest Expense, Operating | $290.00 Million |
Gross Profit | $10.97 Billion |
Net Income/Loss | $1.79 Billion |
Costs And Expenses | $13.71 Billion |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Wages | $1.11 Billion |
Fixed Assets | $3.07 Billion |
Accounts Payable | $907.00 Million |
Inventory | $2.75 Billion |
Assets | $38.08 Billion |
Noncurrent Liabilities | $11.21 Billion |
Liabilities And Equity | $38.08 Billion |
Liabilities | $17.12 Billion |
Other Current Assets | $6.01 Billion |
Other Current Liabilities | $3.89 Billion |
Equity Attributable To Noncontrolling Interest | $248.00 Million |
Current Assets | $8.76 Billion |
Other Non-current Assets | $20.49 Billion |
Equity Attributable To Parent | $20.71 Billion |
Equity | $20.96 Billion |
Current Liabilities | $5.91 Billion |
Noncurrent Assets | $29.32 Billion |
Intangible Assets | $5.75 Billion |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Related Companies
View additional S&P 500 companies similar to Boston Scientific Corp. (BSX)
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.